Results 51 to 60 of about 26,553 (248)

Retargeted adenoviruses for radiation-guided gene delivery [PDF]

, 2016
The combination of radiation with radiosensitizing gene delivery or oncolytic viruses promises to provide an advantage that could improve the therapeutic results for glioblastoma. X-rays can induce significant molecular changes in cancer cells.
A Beetz, AP Patel, BL Davidson, C Roller, Cancer Genome Atlas Research Network, D E Hallahan, DA Boothman, DA Reardon, DA Spencer, DE Hallahan, DY Dadey, F Tameire, G Bajocchi, H Hsu, H Li, H Yan, HO McCarthy, JJ Mezhir, K Daino, L N Kaliberova, LM Hendershot, M Gonzalez-Gronow, M Hamdi, M Martin, M Westphal, MA Arap, MJ Gray, N Belousova, N Mittereder, R Datta, R Stupp, R Stupp, RJ Passarella, RR Weichselbaum, S A Kaliberov, S Akli, S Mittal, S Parisi, S Takahashi, SA Kaliberov, SC Noureddini, SL Eck, SS Talibi, T Ichikawa, TA Ajith, TC He, Ulasov IV, V Kapoor, VN Krasnykh, WL Blalock, WW Zhang, X Xing, Y Touchefeu, Y Zhang, YL Tsai   +54 more
core   +2 more sources

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Oncolytic virotherapy using neural stem cells as a novel treatment option for glioblastoma multiforme

MedComm – Oncology, 2023
The most deadly and aggressive form of brain cancer is called a glioblastoma multiforme. Following diagnosis, the median duration of survival is only 14 months.
Tanvir Ahmed
doaj   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source

Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients. [PDF]

, 2019
Neoantigen vaccines involving multi-peptides and poly-epitope-encoding RNA or DNA have undergone early phase clinical testing with modest reported antitumor effects [ 1].
Bouvet, Michael, Carter, Corey, Larson, Chris, Morris, John C, Oronsky, Bryan, Reid, Tony R   +5 more
core   +1 more source

Macrophage Extracellular Traps in Immunity and Cancer

Advanced Science, EarlyView.
As a macrophage‐mediated innate defense mechanism, the dysregulated release of METs drives chronic inflammation and influences tumor progression. Furthermore, METs exhibit a functional duality within the tumor microenvironment, capable of both promoting and suppressing tumor development.
Junyao Li, Eugenie Nepovimova, Adam Grundel, Lukas Peter, Qinghua Wu, Kamil Kuca   +5 more
wiley   +1 more source

Rational engineering of microRNA-regulated viruses for cancer gene therapy [PDF]

, 2013
MicroRNAs (miRNAs) are small noncoding RNA molecules that have important regulatory roles in a wide range of biological processes. miRNAs are often expressed in a tissue- and/or differentiation state-specific patterns, and it is estimated that miRNAs can
Ylösmäki, Erkko
core  

Measles virus causes immunogenic cell death in human melanoma [PDF]

, 2011
Oncolytic viruses (OV) are promising treatments for cancer, with several currently undergoing testing in randomised clinical trials. Measles virus (MV) has not yet been tested in models of human melanoma.
Bond, Jacquelyn, Donnelly, Oliver G, Errington-Mais, Fiona, Hadac, Elizabeth, Harrington, Kevin, Jennings, Victoria, Melcher, Alan A, Pandha, Hardev, Peach, Howard, Phillips, Roger M, Russell, Stephen, Scott, Karen, Selby, Peter, Steele, Lynette, Vile, Richard   +14 more
core   +1 more source

Fusogenic Viruses in Oncolytic Immunotherapy [PDF]

Cancers, 2018
Oncolytic viruses are under intense development and have earned their place among the novel class of cancer immunotherapeutics that are changing the face of cancer therapy. Their ability to specifically infect and efficiently kill tumor cells, while breaking immune tolerance and mediating immune responses directed against the tumor, make oncolytic ...
Teresa Krabbe, Jennifer Altomonte
openaire   +3 more sources

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source